Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN.

Yuri GorelikShay FreilichShiran Gerassy-VainbergSigal PressmanChagit FrissAlexandera BlattGili FochtYiska Loewenberg WeisbandShira GreenfeldRevital KarivNathan LedermanIris DotanNaama Geva-ZatorskyShai Shlomo Shen-OrrYechezkel KashiYehuda Chowersnull null

Published in: Gut (2021)

ADA production is associated with the microbial composition. The risk of ADA development during anti-TNF therapy can possibly be reduced by avoidance of cephalosporins and penicillin-BLIs, or by treatment with fluoroquinolones or macrolides.

Keyphrases

rheumatoid arthritis
end stage renal disease
newly diagnosed
ejection fraction
microbial community
prognostic factors
emergency department
mesenchymal stem cells
patient reported outcomes
cell therapy
drug induced
patient reported